Aspira Women`s Health Overview
Valuation check: AWH's ROE is 165.15%, above the Healthcare sector average of 22.76%.
Get informed when a big investor buys or sells
+ Follow165.15%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for AWH is 165.15%. That is above the Healthcare sector average of 22.76%. Investors often review this figure alongside Aspira Women`s Health's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, AWH currently prints 165.15% for ROE, while the sector average sits near 22.76%. That is roughly 625.5% above the sector mean. Large gaps often invite a closer look at Aspira Women`s Health's growth, margins, and balance sheet.
Return on Equity shows how effectively Aspira Women`s Health converts resources into returns. At 165.15%, AWH may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting AWH's ROE (165.15%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Aspira Women`s Health's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
